** Vaccine maker Moderna's MRNA.O shares down 4.3% at $33.71
** Brokerage Berenberg cuts PT to $30 from $33, maintains rating to "hold"
** The new PT represents 14.7% downside to stock's last close on Wednesday
** Berenberg sees multiple headwinds for MRNA which include a poor commercial outlook for its respiratory vaccines, and an unsupportive U.S. political environment
** Sanofi's SASY.PA entry into the COVID-19 market with the Novavax NVAX.O vaccine will increase pricing pressure and reduce MRNA's market share, brokerage says
** "Moderna will not meet its guidance to break even by 2028 on our forecasts," brokerage adds
** Two brokerages rate stock "buy" or higher, seven "hold" or equivalent, and one "underperform"; their median PT is $54.51, according to data compiled by LSEG
** MRNA has fallen 63.2% in the past 12 months
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。